Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – Should You Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares saw an uptick in trading volume on Thursday. Approximately 608,157 shares traded hands during trading, an increase of 133% from the average daily volume of 260,611 shares. The stock last traded at $22.6575 and had previously closed at $21.52.

Analysts Set New Price Targets

Several research firms have recently commented on CHGCY. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 1.3%

The firm has a market cap of $73.74 billion, a price-to-earnings ratio of 23.34 and a beta of 0.60. The company has a 50 day moving average of $20.72 and a 200 day moving average of $24.45.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Tuesday, October 27th. The company reported $0.27 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 24.91% and a net margin of 35.63%. The firm had revenue of $2.54 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Equities analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.